Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, China

Table 1

Baseline demographic, anthropometric, and disease characteristics between the study groups.

	Liraglutide	Dapagliflozin	/ value	value
Age, years			0.104	0.917
Male, (%)	83 (58.0%)	107 (64.5%)	1.335^#	0.248
Urban residence patients, (%)	103 (72.0%)	114 (68.7%)	0.413^#	0.520
Smoking history, (%)	60 (42.0%)	73 (44.0%)	0.128^#	0.721
Drinking history, (%)	22 (15.4%)	28 (16.9%)	0.125^#	0.724
DM family history, (%)	106 (74.1%)	103 (62.0%)	5.119^#	0.024
Hypertension, (%)	108 (75.5%)	126 (75.9%)	0.006^#	0.938
CHD, (%)	29 (20.3%)	26 (15.7%)	1.119^#	0.290
T2DM duration (years)			0.504	0.615
SBP (mmHg)			-0.088	0.930
DBP (mmHg)			-1.442	0.150
Body weight (kg)			0.693	0.489
BMI (kg/m^2)			1.212	0.226
TSH			1.104	0.272
FT4			1.737	0.085
Tg			-1.248	0.213
LDL-C			2.090	0.038
BUN			-0.266	0.791
Scr			-2.261	0.025
ALT			-1.878	0.062
AST			-1.028	0.305
HbA1c (%)			0.773	0.440
FPG (mmol/l)			-1.048	0.295
2hPG (mmol/l)			-1.118	0.264
PPGE (mmol/l)			-0.079	0.937
HOMA-IR			-1.629	0.124
Background medication, (%)
Metformin+SU	40 (28.0%)	51 (30.7%)	0.280^#	0.597
ACEI/ARB	80 (55.9%)	95 (56.5%)	0.011^#	0.915
Aspirin	26 (18.2%)	29 (17.3%)	0.045^#	0.832
Statins	51 (35.7%)	50 (29.8%)	1.227^#	0.268

Abbreviations: DM: diabetes mellitus; CHD: coronary atherosclerotic heart disease; T2DM: type 2 diabetes mellitus; SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; Tg: triglycerides; LDL-C: low-density lipoprotein cholesterol; BUN: blood urea nitrogen; Scr: serum creatinine; ALT: alanine aminotransferase; AST: aspartate aminotransferase; FPG: fasting peripheral blood glucose; 2hPG: 2 h postprandial peripheral blood glucose; PPGE: 2-hour incremental postprandial glucose excursion; SU: sulfonylurea; HOMA-IR: homeostatic model assessment insulin resistance index; value; ^# value.